血管紧张素Ⅱ受体阻滞剂与利尿剂联合应用研究进展  

Research Advances on Combination Therapy with Angiotensin Ⅱ Receptor Blocker and Diuretic

作　　者：牟建军[1] 任珂宇[1] 

机构地区：[1]西安交通大学第一附属医院,陕西西安710061

出　　处：《心血管病学进展》2011年第1期7-9,共3页Advances in Cardiovascular Diseases

摘　　要：高血压是目前全球发病率最高的疾病之一,也是心脑血管疾病最常见、可控制的危险因素。合理的联合降压可以提高血压控制率,保护靶器官,降低心血管疾病致死和致残率是目前治疗的主要方案及目标。通过对新近关于血管紧张素Ⅱ受体阻滞剂与利尿剂联合应用研究的综合分析,阐述其在高血压治疗方面的合理性、重要作用及优越性,以期为高血压的联合治疗提供一定的循证医学依据。Hypertension is one of the world＇s highest incidence of the diseases,and is also the most common but controllable risk factor of the cardio-cerebral-vascular disease.Reasonable combination therapy to improve blood pressure control,protect the target organs,reduce the mortality and morbidity of the cardiovascular disease is currently the main treatment strategy and goals.We will elaborate the rationality,the important role and the advantages of the combination of angiotensinⅡreceptor blocker and diuretic through a comprehensive analysis from the recent studies,in order to provide certain evidence-based medical support for the management of hypertension.

关 键 词：血管紧张素Ⅱ受体阻滞剂 利尿剂 联合降压 

分 类 号：R544.1[医药卫生—心血管疾病]